Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
McKinsey
Express Scripts
Merck
AstraZeneca

Last Updated: June 27, 2022

Investigational Drug Information for CB-839


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug CB-839?

CB-839 is an investigational drug.

There have been 21 clinical trials for CB-839. The most recent clinical trial was a Phase 2 trial, which was initiated on September 6th 2017.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Renal Cell, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Calithera Biosciences, Inc, National Cancer Institute (NCI), and Case Comprehensive Cancer Center.

There are seventeen US patents protecting this investigational drug and one hundred and seventy-four international patents.

Recent Clinical Trials for CB-839
TitleSponsorPhase
CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer PatientsUniversity of Alabama at BirminghamPhase 1
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 1
Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy SubjectsNovotech (Australia) Pty LimitedPhase 1

See all CB-839 clinical trials

Clinical Trial Summary for CB-839

Top disease conditions for CB-839
Top clinical trial sponsors for CB-839

See all CB-839 clinical trials

US Patents for CB-839

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CB-839 See Plans and Pricing Combination therapy with glutaminase inhibitors Calithera Biosciences, Inc. (South San Francisco, CA) See Plans and Pricing
CB-839 See Plans and Pricing Compositions and methods of treating cancer harboring PIKC3A mutations Case Western Reserve University (Cleveland, OH) See Plans and Pricing
CB-839 See Plans and Pricing Combination therapy with glutaminase inhibitors and immuno-oncology agents Calithera Biosciences, Inc. (South San Francisco, CA) See Plans and Pricing
CB-839 See Plans and Pricing Combination therapy with glutaminase inhibitors Calithera Biosciences, Inc. (South San Francisco, CA) See Plans and Pricing
CB-839 See Plans and Pricing Crystal forms of glutaminase inhibitors Calithera Biosciences, Inc. (South San Francisco, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CB-839

Drugname Country Document Number Estimated Expiration Related US Patent
CB-839 China CN109982703 2036-08-25 See Plans and Pricing
CB-839 European Patent Office EP3503893 2036-08-25 See Plans and Pricing
CB-839 Japan JP2019524852 2036-08-25 See Plans and Pricing
CB-839 World Intellectual Property Organization (WIPO) WO2018039441 2036-08-25 See Plans and Pricing
CB-839 Australia AU2016335991 2035-10-05 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
McKinsey
Express Scripts
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.